JP2014526558A5 - - Google Patents

Download PDF

Info

Publication number
JP2014526558A5
JP2014526558A5 JP2014531995A JP2014531995A JP2014526558A5 JP 2014526558 A5 JP2014526558 A5 JP 2014526558A5 JP 2014531995 A JP2014531995 A JP 2014531995A JP 2014531995 A JP2014531995 A JP 2014531995A JP 2014526558 A5 JP2014526558 A5 JP 2014526558A5
Authority
JP
Japan
Prior art keywords
romidepsin
azacitidine
use according
amount
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014531995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014526558A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/056485 external-priority patent/WO2013043967A1/en
Publication of JP2014526558A publication Critical patent/JP2014526558A/ja
Publication of JP2014526558A5 publication Critical patent/JP2014526558A5/ja
Pending legal-status Critical Current

Links

JP2014531995A 2011-09-23 2012-09-21 リンパ腫の治療に使用するためのロミデプシン及び5−アザシチジン Pending JP2014526558A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161538734P 2011-09-23 2011-09-23
US61/538,734 2011-09-23
US201261698441P 2012-09-07 2012-09-07
US61/698,441 2012-09-07
PCT/US2012/056485 WO2013043967A1 (en) 2011-09-23 2012-09-21 Romidepsin and 5 - azacitidine for use in treating lymphoma

Publications (2)

Publication Number Publication Date
JP2014526558A JP2014526558A (ja) 2014-10-06
JP2014526558A5 true JP2014526558A5 (enExample) 2016-02-04

Family

ID=47045157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014531995A Pending JP2014526558A (ja) 2011-09-23 2012-09-21 リンパ腫の治療に使用するためのロミデプシン及び5−アザシチジン

Country Status (12)

Country Link
US (1) US20130085115A1 (enExample)
EP (1) EP2758067A1 (enExample)
JP (1) JP2014526558A (enExample)
KR (1) KR20140069225A (enExample)
CN (1) CN104114182A (enExample)
AU (1) AU2012312308B2 (enExample)
CA (1) CA2849708A1 (enExample)
HK (1) HK1200330A1 (enExample)
IL (1) IL231636A0 (enExample)
MX (1) MX2014003467A (enExample)
WO (1) WO2013043967A1 (enExample)
ZA (1) ZA201402151B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195634A1 (en) * 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
WO2018009855A1 (en) * 2016-07-07 2018-01-11 MiRagen Therapeutics, Inc. Methods for treating cutaneous t-cell lymphoma (ctcl) with mir-155 inhibitors
WO2021186855A1 (ja) * 2020-03-16 2021-09-23 株式会社マンダム T細胞性リンパ腫の指標の検出方法、及びその利用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
JPH064872A (ja) 1992-06-19 1994-01-14 Sony Corp 光ディスク再生装置
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
AU2001280109A1 (en) 2000-09-01 2002-03-22 Fujisawa Pharmaceutical Co. Ltd. A method of producing fr901228
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
EP1482418A1 (en) 2003-05-28 2004-12-01 Sap Ag A data processing method and system
ES2444890T3 (es) * 2006-03-31 2014-02-27 Erasmus University Medical Center Rotterdam Nueva composición para el control del crecimiento tumoral
US20100137239A1 (en) * 2006-04-24 2010-06-03 Gloucester Pharmaceuticals Gemcitabine combination therapy
CA2654566A1 (en) * 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
US20110269699A1 (en) * 2008-10-24 2011-11-03 Mitchell Keegan Cancer therapy

Similar Documents

Publication Publication Date Title
JP2013527232A5 (enExample)
JP2014532704A5 (enExample)
CY1116727T1 (el) Θεραπεια πολλαπλης σκληρυνσης me laquinimod
JP2011515481A5 (enExample)
PH12013501790B1 (en) Use of dpp iv inhibitors
JP2009515901A5 (enExample)
JP2014530874A5 (enExample)
JP2009539769A5 (enExample)
JP2006515883A5 (enExample)
MX2010010026A (es) Agente para tratar enfermedad.
JP2016539156A5 (enExample)
JP2012517427A5 (enExample)
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2013541583A5 (enExample)
NZ612717A (en) Treatment of pain associated with dislocation of basal endometrium
NZ608266A (en) Administration of lorcaserin to individuals with renal impairment
JP2014526558A5 (enExample)
JP2015507020A5 (enExample)
DK1750716T3 (da) Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin
NZ591496A (en) A medicinal comprising ibuprofen and paracetamol and treatment for arthritis
JP2011500589A5 (enExample)
JP2009516719A5 (enExample)
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
JP2013540734A5 (enExample)